1. Home
  2. CCBG vs OMER Comparison

CCBG vs OMER Comparison

Compare CCBG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital City Bank Group

CCBG

Capital City Bank Group

HOLD

Current Price

$51.52

Market Cap

874.1M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$18.96

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCBG
OMER
Founded
1895
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
874.1M
844.6M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
CCBG
OMER
Price
$51.52
$18.96
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$50.00
$32.50
AVG Volume (30 Days)
48.1K
2.2M
Earning Date
04-20-2026
05-14-2026
Dividend Yield
2.34%
N/A
EPS Growth
15.38
98.15
EPS
0.92
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
$6.25
N/A
Revenue Next Year
$3.17
$233.22
P/E Ratio
$56.05
$24.61
Revenue Growth
N/A
N/A
52 Week Low
$38.27
$3.94
52 Week High
$53.60
$19.65

Technical Indicators

Market Signals
Indicator
CCBG
OMER
Relative Strength Index (RSI) 53.30 71.49
Support Level $50.98 $18.00
Resistance Level $52.10 $19.65
Average True Range (ATR) 0.98 0.88
MACD -0.13 -0.14
Stochastic Oscillator 54.14 75.10

Price Performance

Historical Comparison
CCBG
OMER

About CCBG Capital City Bank Group

Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: